$12.12
-0.88-6.74%
Last update: Nov 12, 4:05 PM
4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote, News & History
FDMTNASDAQ
4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to an 87% cut in treatment burden.
You can purchase shares of 4D Molecular Therapeutics (NASDAQ:FDMT) through any online brokerage.
Other companies in 4D Molecular Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
4D Molecular Therapeutics has a consensus price target of $32.18.
The stock price for 4D Molecular Therapeutics (NASDAQ: FDMT) is $11.93 last updated November 12, 2026 at 4:05 PM EST.
There are no upcoming dividends for 4D Molecular Therapeutics.
4D Molecular Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for 4D Molecular Therapeutics.
4D Molecular Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet...
